search icon
      blog search icon

      Mesoblast Stock Price History and Quote Analysis: Insights for Investors

      Mesoblast Limited

      (NASDAQ:MESO)

      $1.02

      -0.08 (-7.27%)

      Open: 12:30 PM

      Mesoblast Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      Mesoblast Stock Price Today

      Mesoblast Limited (MESO) stock declined over -6.42% intraday to trade at $1.02 a share on NASDAQ. The stock opened with a gain of 5.45% at $1.16 and touched an intraday high of $1.21, falling -7.27% against the last close of $1.10. The Mesoblast Limited in stock market went to a low of $1.13 during the session.

      Mesoblast Stock Snapshot

      $1.10

      Prev. Close

      207.51 Million

      Market Cap

      $1.13

      Day Low

      $1.16

      Open

      N/A

      Number of Shares

      $1.21

      Day High

      N/A

      P/E ratio

      -0.53

      EPS (TTM)

      0.09

      Cash Flow per Share

      N/A

      Free Float in %

      0.62

      Book Value

      409186.00

      Volume

      Mesoblast Stock Price History Chart

      DateOpenHighLowCloseVolume

      Contact Details

      55 Collins Street
      Melbourne, VIC 3000
      AU

      Website:https://www.mesoblast.com

      Contact #:61 3 9639 6036

      Company Information

      EmployeesN/A

      Beta3.44

      Sales or Revenue$7.5 Million

      5Y Sales Change5.23%

      Fiscal Year EndsJun. 2023

      SectorHealthcare

      IndustryBiotechnology

      About Company

      Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

      Peers

      Frequently Asked Questions

      icon

      What is the current Mesoblast Limited (MESO) stock price?

      Mesoblast Limited (NASDAQ: MESO) stock price is $1.02 in the last trading session. During the trading session, MESO stock reached the peak price of $1.21 while $1.13 was the lowest point it dropped to. The percentage change in MESO stock occurred in the recent session was -6.42% while the dollar amount for the price change in MESO stock was -$0.07.

      icon

      MESO's industry and sector of operation?

      The NASDAQ listed MESO is part of Biotechnology industry that operates in the broader Healthcare sector. Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.

      icon

      Who are the executives of MESO?

      Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)
      Gen. Counsel & Corporation Executive
      Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
      Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director
      Dr. Philip R. Krause M.B.A., M.D., M.S.
      Strategic Advisor & Director
      Dr. Philip R. Krause M.B.A., M.D., M.S.
      Strategic Advisor & Non Exec. Director

      icon

      How MESO did perform over past 52-week?

      MESO's closing price is 0.55% higher than its 52-week low of $1.13 where as its distance from 52-week high of $5.12 is -0.24%.

      icon

      How many employees does MESO have?

      Number of MESO employees currently stands at N/A. MESO operates from 55 Collins Street, Melbourne, VIC 3000, AU.

      icon

      Link for MESO official website?

      Official Website of MESO is: https://www.mesoblast.com

      icon

      How do I contact MESO?

      MESO could be contacted at phone #61 3 9639 6036 and can also be accessed through its website. MESO operates from 55 Collins Street, Melbourne, VIC 3000, AU.

      icon

      How many shares of MESO are traded daily?

      MESO stock volume for the day was 409186.00 shares. The average number of MESO shares traded daily for last 3 months was 139.61 Thousands.

      icon

      What is the market cap of MESO currently?

      The market value of MESO currently stands at $207.51 Million with its latest stock price at $1.02 and N/A of its shares outstanding.